多血症の世界市場（2025年～2033年）

世界の多血症の市場規模は、2024年に58億9,000万米ドルに達し、2033年には124億1,000万米ドルに達すると予測され、予測期間2025年～2033年にはCAGR6.7％で成長する見込みです。

多血症は赤血球増加症としても知られ、ヘモグロビンおよびヘマトクリット値の上昇をもたらす赤血球量の増加を特徴とする疾患です。亜型である真性多血症は、複数の赤血球系譜の過剰産生に関連することがあります。赤血球増加症の臨床的意義は、血液の過粘稠性による血栓のリスク、および白血病の進行の可能性と関連しています。この活動では、真性多血症の評価、治療、および潜在的合併症について論じ、その診断と治療における専門職チームの役割を強調します。

市場力学：

促進要因と抑制要因

多血症の有病率の上昇

多血症、特に真性多血症（PV）の増加が多血症市場の成長を促進しています。喫煙、肥満、慢性呼吸器疾患などの生活習慣がこの疾患の一因となっており、効果的な治療に対する需要が高まっています。

患者数の増加により、細胞還元療法、代謝拮抗薬、支持療法などさまざまな治療オプションが必要とされています。また、合併症の蔓延により、個々の患者に合わせた治療アプローチが必要となります。多血症の罹患率が増加するにつれ、医療提供者は患者ケアと転帰の改善に注力しなければなりません。

例えば、Leukemia and Lymphoma Societyによると、PVは東欧系のユダヤ人に多くみられます。PVの発症率は男性10万人当たり約2.8人、女性10万人当たり約1.3人で、有病率は10万人当たり22人です。診断時の平均年齢は60～65歳で、30歳未満の症例はまれです。この変異遺伝子の正確な役割はまだ研究中です。

薬剤に関連する合併症

多血症、赤血球数の上昇を伴う疾患では、しばしば薬剤を用いた治療が必要となります。ヒドロキシ尿素のような薬剤は、骨髄抑制、貧血、感染リスクの増加などの副作用を引き起こす可能性があります。インターフェロンαは、インフルエンザ様症状、疲労、気分障害を引き起こし、患者のQOLに影響を与える可能性があります。抗凝固薬は出血や胃腸障害を引き起こす可能性があります。特定の薬剤の長期使用は、二次がんや臓器毒性を引き起こす可能性があり、定期的なモニタリングが必要です。病態の管理には有効であるにもかかわらず、副作用は重大な課題となる可能性があり、治療上の利益と有害な転帰のバランスを慎重にとる必要があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 多血症の有病率の上昇
  • 抑制要因
    • 薬剤に関連する合併症
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析

第6章 タイプ別

• 原発性多血症
• 二次性多血症
• 偽性多血症

第7章 薬剤クラス別

• 代謝拮抗物質
  • ヒドロキシウレア
  • メトトレキサート
  • シタラビン
• JAK2阻害剤
• 骨髄抑制剤
• 選択的セロトニン再取り込み阻害剤
• 葉酸
• その他

第8章 投与経路別

• 経口
• 静脈内
• 筋肉内

第9章 流通チャネル別

• 院内薬局
• 小売薬局
• オンライン薬局

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第12章 企業プロファイル

• Novartis AG
  • 会社概要
  • 製品ポートフォリオ
    • 製品説明
    • 製品の主要業績評価指標（KPI）
    • 実績および予測の製品販売
    • 製品販売量
  • 財務概要
    • 企業収益
    • 地域別収益分配
    • 収益予測
  • 主な発展
    • 合併と買収
    • 主な製品開発活動
    • 規制当局の承認等
  • SWOT分析
• Incyte Corporation
• Bristol-Myers Squibb Company
• PharmaEssentia Corporation
• TAJ LIFE SCIENCES PVT. LTD
• Genetec Lifesciences
• Teva Pharmaceuticals
• Medyra Pharmaceuticals
• Viatris
• Apotex Inc
• DiscMedicine
  • パイプライン製品の説明
  • 製品の主要業績評価指標（KPI）
  • 主な活動
  • 市場参入のタイムライン
  • 製品普及率
  • 売上推定と予測
• Silence Therapeutics
• Takeda Pharmaceuticals

第12章 付録

The global polycythemia market reached US$ 5.89 billion in 2024 and is expected to reach US$ 12.41 billion by 2033, growing at a CAGR of 6.7% during the forecast period 2025-2033.

Polycythemia, also known as erythrocytosis, is a condition characterized by increased red blood cell mass, resulting in higher hemoglobin and hematocrit levels. Polycythemia vera, a subtype, can be linked to overproduction of multiple erythrocytic lineages. The clinical significance of erythrocytosis is linked to the risk of thrombotic events due to blood hyperviscosity, and the potential for leukemia progression. This activity discusses the evaluation, treatment, and potential complications of polycythemia vera, emphasizing the interprofessional team's role in its diagnosis and treatment.

Market Dynamics: Drivers & Restraints

Rise in the Prevalence of Polycythemia

The rise in polycythemia, particularly polycythemia vera (PV), is driving the growth of the polycythemia market. Lifestyle factors like smoking, obesity, and chronic respiratory diseases contribute to the condition, increasing demand for effective treatments.

The growing patient population necessitates a variety of therapeutic options, including cytoreductive therapies, antimetabolites, and supportive treatments. The prevalence of associated comorbidities also necessitates tailored treatment approaches. As polycythemia incidence increases, healthcare providers must focus on improving patient care and outcomes.

For instance, according to Leukemia and Lymphoma Society, PV is more prevalent among Jews of Eastern European descent. The incidence of PV is around 2.8 per 100,000 men and 1.3 per 100,000 women, with a prevalence of 22 cases per 100,000 people. The average age at diagnosis is 60-65 years, with rare cases in individuals under 30 years. The exact role of this mutated gene is still under study. and outcomes.

Complications Associated with the Drugs

Polycythemia, a condition with elevated red blood cell counts, often requires drug-based treatments. Medications like hydroxyurea can cause side effects like bone marrow suppression, anemia, and increased infection risk. Interferon-alpha may cause flu-like symptoms, fatigue, and mood disturbances, impacting patient quality of life. Anticoagulants may cause bleeding and gastrointestinal issues. Long-term use of certain drugs can lead to secondary cancers and organ toxicity, necessitating regular monitoring. Despite their effectiveness in managing the condition, side effects can pose significant challenges, requiring a careful balance between therapeutic benefits and adverse outcomes.

For more details on this report - Request for Sample

Segment Analysis

The global polycythemia market is segmented based on type, drug class, route of administration, distribution channel, region.

By Drug Class:

Antimetabolites segment is expected to dominate the Polycythemia market share

The antimetabolites segment holds a major portion of the polycythemia market share and is expected to continue to hold a significant portion of the polycythemia market share during the forecast period.

Antimetabolites, such as methotrexate and cytarabine, are crucial in managing polycythemia vera (PV) by reducing blood cell proliferation in the bone marrow. They disrupt DNA and RNA synthesis, inhibiting erythroid progenitor cells responsible for excessive red blood cell production. These drugs are beneficial for patients who may not respond well to first-line treatments or experience side effects. They reduce hematocrit levels and alleviate hyperviscosity symptoms, improving clinical outcomes.

Hydroxyurea (HU) is a widely used drug in clinical practice, particularly as a cytoreductive treatment for high-risk polycythemia vera (PV) patients. It is well-tolerated, inexpensive, and has a convenient oral formulation. However, the wider availability of drugs that modify PV's course, including reducing the burden of the mutated JAK2 V617F allele, necessitates defining more precise clinical response criteria.

Route of Administration:-

Oral segment is the fastest-growing segment in Polycythemia market share

The oral segment is the fastest-growing segment in the polycythemia market share and is expected to hold the market share over the forecast period.

The oral route of administration has high importance in the polycythemia vera (PV) treatment market. The reason is patient compliance, easy administration and most importantly cost-effectiveness. Hydroxyurea is one of the most commonly prescribed medicines for PV treatment through the oral route. An oral drug is generally preferred by patients because it is non-invasive. This route allows easy drug administration into the body and ensures treatment adherence, which is important because it is a chronic disease.

Additionally, oral medications tend to be more convenient in use than other routes like intravenous or subcutaneous. This holds well in the market, where oral forms constitute an estimated 90% of products intended for human use49 overall. The predominance of the oral route concerning PV therapy indicates its importance in improving patient outcomes and simplifying treatment regimens.

Geographical Analysis

North America is expected to hold a significant position in the Polycythemia market share

North America holds a substantial position in the polycythemia market and is expected to hold most of the market share due to high prevalence of polycythemia vera and secondary polycythemia, influenced by lifestyle factors and chronic diseases like COPD and sleep apnea. The region's advanced healthcare infrastructure facilitates early diagnosis and effective blood disorder management. Pharmaceutical companies' investment in research and development has led to novel therapies and improved treatment options.

Additionally, the market will experience a rapid expansion in the coming years due to the major pharmaceutical companies' research initiatives to develop new drugs. Thus, rise of diseases and product developments, in the region helps to accelerate the region growth.

For instance, on July 2023, the United States Food and Drug Administration (FDA) has granted Fast Track Designation to the development initiatives of selinexor for the treatment of patients with myelofibrosis, including primary myelofibrosis, post-essential thrombocythemia myelofibrosis, and post-polycythemia vera myelofibrosis, according to Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company introducing novel cancer therapies. Thus, all of those factors aid in accelerating market expansion in the region.

Europe is growing at the fastest pace in the Polycythemia market

Europe holds the fastest pace in the polycythemia market and is expected to hold most of the market share due to improved diagnostic testing for early detection, which, in turn, has increased the number of patients treated. Robust improvement of this advancement is vital, as improved management and outcome of the disease can be achieved by timely intervention.

Additionally, awareness of polycythemia vera within the healthcare provider communities and the patient population continues to advance, resulting in increased screening and diagnosis. Robust healthcare infrastructures, such as Germany (which accounts for the largest market share in Europe), contribute to all of this. Rising healthcare expenditure and investments in R&D have thus furthered the introduction of new therapies and treatment options making the market wider.

For instance, according to National Institute For Health and Care Excellence, polycythemia vera is a common condition affecting people aged 60 and older, with a UK prevalence of 6.8 per 100,000. Approximately 5% to 15% of those with polycythaemia vera develop myelofibrosis, and 5 to 10% develop acute myeloid leukaemia.

Competitive Landscape

The major global players in the polycythemia market include Novartis AG, Incyte Corporation, Bristol-Myers Squibb Company, PharmaEssentia Corporation, TAJ LIFE SCIENCES PVT. LTD, Genetec Lifesciences, Teva Pharmaceuticals, Medyra Pharmaceuticals, Viatris, Apotex Inc and among others.

Key Developments

• In September 2024, PharmaEssentia Corporation, a Taiwan-based biopharmaceutical innovator, has signed an exclusive licensing agreement with FORUS Therapeutics Inc for the registration and distribution of BESREMi (ropeginterferon alfa-2b-njft) for the treatment of polycythemia vera (PV) in Canada, leveraging its expertise in hematology and oncology.
• In January 2024, a new treatment for polycythemia vera, a potentially fatal blood cancer, has shown potential in controlling overproduction of red blood cells. The drug rusfertide, developed by the Icahn School of Medicine at Mount Sinai, limited excess red blood cell production over 28 weeks, suggesting it could potentially replace traditional phlebotomy, a common treatment that has been a burden for many patients.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global polycythemia market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Route of Administration & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Drug Class
• 3.3. Snippet by Route of Administration
• 3.4. Snippet by End User
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rise in the Prevalence of Polycythemia
  • 4.1.2. Restraints
    • 4.1.2.1. Complications Associated with the Drugs
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. By Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 6.1.2. Market Attractiveness Index, By Type
• 6.2. Primary polycythemia*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Secondary polycythemia
• 6.4. Pseudopolycythemia

7. By Drug Class

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 7.1.2. Market Attractiveness Index, By Drug Class
• 7.2. Antimetabolites*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.2.3. Hydroxyurea
  • 7.2.4. Methotrexate
  • 7.2.5. Cytarabine
• 7.3. JAK2 inhibitors
• 7.4. Myelosuppressive Agents
• 7.5. Selective Serotonin Reuptake Inhibitors
• 7.6. Folic acid
• 7.7. Others

8. By Route of Administration

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 8.1.2. Market Attractiveness Index, By Route of Administration
• 8.2. Oral*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Intravenous
• 8.4. Intramuscular

9. By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospital Pharmacies*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Retail Pharmacies
• 9.4. Online Pharmacies

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.7.1. U.S.
    • 10.2.7.2. Canada
    • 10.2.7.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.7.1. Germany
    • 10.3.7.2. U.K.
    • 10.3.7.3. France
    • 10.3.7.4. Spain
    • 10.3.7.5. Italy
    • 10.3.7.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.7.1. Brazil
    • 10.4.7.2. Argentina
    • 10.4.7.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7.1. China
    • 10.5.7.2. India
    • 10.5.7.3. Japan
    • 10.5.7.4. South Korea
    • 10.5.7.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

Key Market Players

• 12.1. Novartis AG*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio
    • 12.1.2.1. Product Description
    • 12.1.2.2. Product Key Performance Indicators (KPIs)
    • 12.1.2.3. Historic and Forecasted Product Sales
    • 12.1.2.4. Product Sales Volume
  • 12.1.3. Financial Overview
    • 12.1.3.1. Company Revenue's
    • 12.1.3.2. Geographical Revenue Shares
    • 12.1.3.3. Revenue Forecasts
  • 12.1.4. Key Developments
    • 12.1.4.1. Mergers & Acquisitions
    • 12.1.4.2. Key Product Development Activities
    • 12.1.4.3. Regulatory Approvals etc.
  • 12.1.5. SWOT Analysis
• 12.2. Incyte Corporation
• 12.3. Bristol-Myers Squibb Company
• 12.4. PharmaEssentia Corporation
• 12.5. TAJ LIFE SCIENCES PVT. LTD
• 12.6. Genetec Lifesciences
• 12.7. Teva Pharmaceuticals
• 12.8. Medyra Pharmaceuticals
• 12.9. Viatris
• 12.10. Apotex Inc
• Similar data will be provided for each market player.

Emerging Market Players

• 12.11. DiscMedicine*
  • 12.11.1. Pipeline Products Description
  • 12.11.2. Product Key Performance Indicators (KPIs)
  • 12.11.3. Key Activities
  • 12.11.4. Market Entry Timelines
  • 12.11.5. Product Penetration Rate
  • 12.11.6. Sales Estimation and Projections
• 12.12. Silence Therapeutics
• 12.13. Takeda Pharmaceuticals
• Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1 About Us and Services
• 12.2 Contact Us